Inspire Medical Systems (INSP) Stock Forecast & Price Target

Compare

784 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSP Analyst Ratings

Moderate Buy

6 Buy

7 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Inspire

Medical Systems

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSP Stock 12 Month Forecast

Average Price Target

$105.50

▲(28.99% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is $105.50 with a high forecast of $150.00 and a low forecast of $82.00. The average price target represents a 28.99% change from the last price of $81.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"$71","194":"$194","101.75":"$101.8","132.5":"$132.5","163.25":"$163.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,101.75,132.5,163.25,194],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.08,78.07384615384615,84.06769230769231,90.06153846153846,96.05538461538461,102.04923076923077,108.04307692307692,114.03692307692307,120.03076923076924,126.02461538461539,132.01846153846154,138.01230769230767,144.00615384615384,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.08,74.65076923076923,77.22153846153846,79.79230769230769,82.36307692307692,84.93384615384615,87.50461538461538,90.07538461538462,92.64615384615385,95.21692307692308,97.78769230769231,100.35846153846154,102.92923076923077,{"y":105.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.08,72.84307692307692,73.60615384615384,74.36923076923077,75.13230769230769,75.89538461538461,76.65846153846154,77.42153846153846,78.18461538461538,78.94769230769231,79.71076923076923,80.47384615384615,81.23692307692308,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":190.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$150.00

Average Price Target$105.50

Lowest Price Target$82.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$78→$94

Buy

14.93%

Upside

Upgraded

11/05/25

AI Generated ArticleAI Generated Article

Richard Newitter

Truist Financial

$90→$84

Hold

2.70%

Upside

Reiterated

11/04/25

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (NASDAQ: TERN), BioNTech SE (NASDAQ: BNTX) and Inspire Medical Systems (NYSE: INSP)

Adam Maeder

Piper Sandler

$150→$135

Buy

65.06%

Upside

Reiterated

11/04/25

Inspire Medical price target lowered to $135 from $150 at Piper SandlerInspire Medical price target lowered to $135 from $150 at Piper Sandler

Robbie Marcus

J.P. Morgan

$82

Hold

0.26%

Upside

Reiterated

11/04/25

J.P. Morgan Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Jonathan Block

Stifel Nicolaus

$100

Hold

22.26%

Upside

Reiterated

11/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (NASDAQ: XENE), Syndax Pharmaceuticals (NASDAQ: SNDX) and Inspire Medical Systems (NYSE: INSP)

Larry Biegelsen

Wells Fargo

$101→$90

Buy

10.04%

Upside

Upgraded

11/04/25

Inspire Medical upgraded to Overweight from Equal Weight at Wells FargoInspire Medical upgraded to Overweight from Equal Weight at Wells Fargo

Daniel Markowitz CFA

Evercore ISI

$125

Buy

52.83%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (NYSE: INSP) and Exact Sciences (NASDAQ: EXAS)

Patrick Wood

Morgan Stanley

$105

Buy

28.38%

Upside

Reiterated

11/04/25

Morgan Stanley Keeps Their Buy Rating on Inspire Medical Systems (INSP)Inspire Medical Systems is rated Overweight with unchanged target pricing and modest EPS estimate revisions.

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

11/04/25

KeyBanc Sticks to Their Hold Rating for Inspire Medical Systems (INSP)

Shagun Singh Chadha

RBC Capital

$150→$125

Buy

52.83%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM) and Inspire Medical Systems (NYSE: INSP)

Michael Sarcone

Jefferies

$160→$85

Hold

3.92%

Upside

Downgraded

10/23/25

Inspire Medical downgraded to Hold from Buy at JefferiesInspire Medical downgraded to Hold from Buy at Jefferies

Mike Kratky

Leerink Partners

$97→$96

Hold

17.37%

Upside

Reiterated

10/14/25

Leerink Partners Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Danielle Antalffy

UBS

$230→$89

Hold

8.82%

Upside

Downgraded

09/23/25

Inspire Medical downgraded to Neutral from Buy at UBSInspire Medical downgraded to Neutral from Buy at UBS

Frank Takkinen

Lake Street

$150

Buy

83.40%

Upside

Reiterated

08/27/25

Lake Street Sticks to Its Buy Rating for Inspire Medical Systems (INSP)

Christopher Pasquale

Nephron

$130

Hold

58.94%

Upside

Downgraded

08/05/25

Inspire Medical Systems (INSP) was downgraded to a Hold Rating at Nephron

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$78→$94

Buy

14.93%

Upside

Upgraded

11/05/25

AI Generated ArticleAI Generated Article

Richard Newitter

Truist Financial

$90→$84

Hold

2.70%

Upside

Reiterated

11/04/25

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (NASDAQ: TERN), BioNTech SE (NASDAQ: BNTX) and Inspire Medical Systems (NYSE: INSP)

Adam Maeder

Piper Sandler

$150→$135

Buy

65.06%

Upside

Reiterated

11/04/25

Inspire Medical price target lowered to $135 from $150 at Piper SandlerInspire Medical price target lowered to $135 from $150 at Piper Sandler

Robbie Marcus

J.P. Morgan

$82

Hold

0.26%

Upside

Reiterated

11/04/25

J.P. Morgan Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Jonathan Block

Stifel Nicolaus

$100

Hold

22.26%

Upside

Reiterated

11/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (NASDAQ: XENE), Syndax Pharmaceuticals (NASDAQ: SNDX) and Inspire Medical Systems (NYSE: INSP)

Larry Biegelsen

Wells Fargo

$101→$90

Buy

10.04%

Upside

Upgraded

11/04/25

Inspire Medical upgraded to Overweight from Equal Weight at Wells FargoInspire Medical upgraded to Overweight from Equal Weight at Wells Fargo

Daniel Markowitz CFA

Evercore ISI

$125

Buy

52.83%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (NYSE: INSP) and Exact Sciences (NASDAQ: EXAS)

Patrick Wood

Morgan Stanley

$105

Buy

28.38%

Upside

Reiterated

11/04/25

Morgan Stanley Keeps Their Buy Rating on Inspire Medical Systems (INSP)Inspire Medical Systems is rated Overweight with unchanged target pricing and modest EPS estimate revisions.

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

11/04/25

KeyBanc Sticks to Their Hold Rating for Inspire Medical Systems (INSP)

Shagun Singh Chadha

RBC Capital

$150→$125

Buy

52.83%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM) and Inspire Medical Systems (NYSE: INSP)

Michael Sarcone

Jefferies

$160→$85

Hold

3.92%

Upside

Downgraded

10/23/25

Inspire Medical downgraded to Hold from Buy at JefferiesInspire Medical downgraded to Hold from Buy at Jefferies

Mike Kratky

Leerink Partners

$97→$96

Hold

17.37%

Upside

Reiterated

10/14/25

Leerink Partners Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Danielle Antalffy

UBS

$230→$89

Hold

8.82%

Upside

Downgraded

09/23/25

Inspire Medical downgraded to Neutral from Buy at UBSInspire Medical downgraded to Neutral from Buy at UBS

Frank Takkinen

Lake Street

$150

Buy

83.40%

Upside

Reiterated

08/27/25

Lake Street Sticks to Its Buy Rating for Inspire Medical Systems (INSP)

Christopher Pasquale

Nephron

$130

Hold

58.94%

Upside

Downgraded

08/05/25

Inspire Medical Systems (INSP) was downgraded to a Hold Rating at Nephron

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inspire Medical Systems

1 Month

xxx

Success Rate

12/23 ratings generated profit

Average Return

+2.53%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.17% of your transactions generating a profit, with an average return of +2.53% per trade.

3 Months

xxx

Success Rate

14/23 ratings generated profit

Average Return

+8.63%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +8.63% per trade.

1 Year

Adam MaederPiper Sandler

Success Rate

15/33 ratings generated profit

Average Return

+7.99%

reiterated a buy rating 5 days ago

Copying Adam Maeder's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +7.99% per trade.

2 Years

xxx

Success Rate

13/33 ratings generated profit

Average Return

-4.25%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 39.39% of your transactions generating a profit, with an average return of -4.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSP Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSP has received 9 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. INSP average Analyst price target in the past 3 months is 105.50.

Each month's total comprises the sum of three months' worth of ratings.

INSP Financial Forecast

INSP Earnings Forecast

Next quarter’s earnings estimate for INSP is $0.67 with a range of $0.61 to $0.77. The previous quarter’s EPS was $0.38. INSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year INSP has Preformed in-line its overall industry.

INSP Sales Forecast

Next quarter’s sales forecast for INSP is $262.57M with a range of $260.00M to $265.70M. The previous quarter’s sales results were $224.50M. INSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year INSP has Preformed in-line its overall industry.

INSP Stock Forecast FAQ

What is INSP’s average 12-month price target, according to analysts?

Based on analyst ratings, Inspire Medical Systems’s 12-month average price target is 105.50.

What is INSP’s upside potential, based on the analysts’ average price target?

Inspire Medical Systems has 28.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSP a Buy, Sell or Hold?

Inspire Medical Systems has a consensus rating of Moderate Buy which is based on 6 buy ratings, 7 hold ratings and 0 sell ratings.

What is Inspire Medical Systems’s price target?

The average price target for Inspire Medical Systems is 105.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $82.00. The average price target represents 28.99% Increase from the current price of $81.79.

What do analysts say about Inspire Medical Systems?

Inspire Medical Systems’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of INSP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Inspire Medical Systems (INSP) Stock Forecast & Price Target

INSP Analyst Ratings

INSP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Inspire Medical Systems

INSP Analyst Recommendation Trends

INSP Financial Forecast

INSP Earnings Forecast

INSP Sales Forecast

INSP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts